We have written a number of articles that we hope will be of interest to you. This includes health guides for various medical conditions; news about drug development and regulatory issues related to Health Canada and the FDA; and other health-related topics. Clicking on the title of a Health Guide will take you to information on that medical condition. Or click on one of the listed topics, such as Industry News or Diabetes. You can also access recent articles by scrolling down the page or clicking an article under ‘Recent Articles’.
Following the success of Ozempic®, Wegovy®, and other GLP-1 receptor agonists, pharmaceutical companies are racing to develop the next wave of metabolic drugs. These new therapies build on the proven benefits of currently approved GLP-1s—lowering blood sugar, supporting weight loss, and reducing cardiovascular risk—while aiming for even greater results in weight management and metabolic health.
Curious about the science behind today’s most talked-about diabetes and weight-management treatments? Our new, four-part blog series on GLP-1 Agonists will break down everything you need to know — from how these drugs work, to their real-world results, side effects, and what’s coming next in the pipeline. Today, we’re covering how someone might choose between GLP-1 molecules,
Curious about the science behind today’s most talked-about diabetes and weight-management treatments? Our new, four-part blog series on GLP-1 Agonists will break down everything you need to know — from how these drugs work, to their real-world results, side effects, and what’s coming next in the pipeline. GLP-1 stands for glucagon-like peptide-1. It’s an incretin
The mRNA technology behind the COVID-19 vaccines that saved millions of lives during the pandemic may also help fight cancer, according to new research published in Nature. Scientists found that the Pfizer and Moderna mRNA vaccines can strengthen the immune system’s ability to recognize and kill tumor cells, even when the vaccines were originally designed
Eli Lilly’s diabetes drug Mounjaro (tirzepatide) is moving closer to approval for children and teens after strong results from a new clinical trial. The phase 3 SURPASS-PEDS study tested the drug in 99 patients ages 10 to 17 who struggled to control their blood sugar with common treatments like metformin and insulin. After 30 weeks,
A groundbreaking study from the University of Auckland has found that a single fecal microbiota transplant (FMT) can provide obese teenagers with years of health benefits. FMT involves transferring gut bacteria from healthy donors to patients—in this case, through capsules swallowed over two days. While the idea may sound unappealing, the results are remarkable. The
Eli Lilly is moving closer to bringing its experimental weight loss pill, orforglipron, to market after releasing positive results from its latest phase 3 clinical trial. The study, called Attain-2, tested the once-daily pill in people who are overweight or obese and also have Type 2 diabetes—a group often harder to treat. The trial found
Novo Nordisk’s popular weight-loss drug Wegovy has just received a new approval from the U.S. Food and Drug Administration (FDA)—this time for treating a serious liver condition called metabolic dysfunction-associated steatohepatitis (MASH). This marks Wegovy’s third approved use, following its approvals for obesity and reducing cardiovascular risk. MASH, once known as NASH, is caused by
